Remember that cell selection through closed system and MULTIPLICATION after selection both contribute to safety. The multiplication process reduces need for extra leuk procedures. I don't know if this was allowed because the screening process did take out patients that could not provide enough precursor material but that may have only been from earlier in the trial. NWBO does have this ability though and they also know that certain cell type characteristics are critical to successful treatment. They have news! Best wishes.
Market Data 
Markets 
AI
